Konsultieren Sie einen Arzt fr eine persnliche Beratung
April 15, 2026: In the updated 503A document, the FDA announced it is removing BPC-157 (both BPC-157 acetate and BPC-157 free base) from Category 2 and scheduling a PCAC meeting for July 23, 2026
Accessed February 23, 2026
By mimicking natural GLP-1s in the body, these medications stimulate the release of insulin to help lower blood sugar after eating
The initial results are encouraging and allow us to hope that we will obtain a first proof of concept within the next two to five years. However, this solution is unlikely to become available to patients for another ten years or so, but it raises hopes for all those whose anosmia does not respond to traditional treatments
There is no established tolerable upper intake level (UL), so even high-dose injections are safe because your system simply eliminates what it cannot use